LEADER 04152nam 22006735 450 001 9910300062203321 005 20200701072045.0 010 $a1-907673-88-1 024 7 $a10.1007/978-1-907673-88-7 035 $a(CKB)3710000000261521 035 $a(EBL)1965087 035 $a(OCoLC)908083155 035 $a(SSID)ssj0001372646 035 $a(PQKBManifestationID)11829436 035 $a(PQKBTitleCode)TC0001372646 035 $a(PQKBWorkID)11305035 035 $a(PQKB)10133309 035 $a(MiAaPQ)EBC1965087 035 $a(DE-He213)978-1-907673-88-7 035 $a(PPN)182093085 035 $a(EXLCZ)993710000000261521 100 $a20141016d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aGuide to Assessment Scales in Parkinson?s Disease /$fby Pablo Martinez-Martin, Carmen Rodriguez-Blazquez, Maria Joćo Forjaz, Kallol Ray Chaudhuri 205 $a1st ed. 2014. 210 1$aTarporley :$cSpringer Healthcare Ltd. :$cImprint: Springer Healthcare,$d2014. 215 $a1 online resource (96 p.) 300 $aDescription based upon print version of record. 311 $a1-907673-87-3 320 $aIncludes bibliographical references at the end of each chapters. 327 $aIntroduction -- Multi-domain scales -- Global severity assessments -- Movement disorders and disability scales -- Comprehensive non-motor symptoms assessments -- Non-motor disorders scales -- Mental aspects scales (cognition and neuropsychiatric symptoms) -- Quality of life scales. 330 $aThis Guide assesses the key clinimetric attributes in the assessment of Parkinson's Disease (PD), with the intention to offer rapid and pragmatic information on the most relevant scales used in PD. Parkinson?s disease affects approximately 4 million people globally and is most commonly seen in people over the age of 50. The disease is a progressive disorder of the nervous system, and presents a number of movement and cognitive symptoms, thereby greatly affecting a patients quality of life. The use of scales for assessment in neurological disorders such as PD arises from the need to quantify disorders and states (such constructs as disability, symptoms, quality of life). Assessment scales are often categorised into two categories: generic (i.e. those scales usable in any health condition), and specific (i.e. scales developed for exclusive use in PD). They can have a variety of components: single-item and multi-item or composite scale; unidimensional and multidimensional; and as disease-centered and patient-centered measures. The creation and validation of scales is complex, with scales undergoing numerous studies to assess criteria such as acceptability, reliability, and responsiveness. In the process of validation of a scale the following attributes should be tested to ascertain whether a scale is an effective instrument of measurement. 606 $aMedicine 606 $aNeurology  606 $aMedical research 606 $aMedicine/Public Health, general$3https://scigraph.springernature.com/ontologies/product-market-codes/H00007 606 $aNeurology$3https://scigraph.springernature.com/ontologies/product-market-codes/H36001 606 $aQuality of Life Research$3https://scigraph.springernature.com/ontologies/product-market-codes/H65000 615 0$aMedicine. 615 0$aNeurology . 615 0$aMedical research. 615 14$aMedicine/Public Health, general. 615 24$aNeurology. 615 24$aQuality of Life Research. 676 $a306 676 $a610 676 $a616.8 700 $aMartinez-Martin$b Pablo$4aut$4http://id.loc.gov/vocabulary/relators/aut$01062071 702 $aRodriguez-Blazquez$b Carmen$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aForjaz$b Maria Joćo$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aChaudhuri$b Kallol Ray$4aut$4http://id.loc.gov/vocabulary/relators/aut 906 $aBOOK 912 $a9910300062203321 996 $aGuide to Assessment Scales in Parkinson?s Disease$92522547 997 $aUNINA